Zevra treatment company's revenue increased by 26%.

Rare disease drug developer Zevra Therapeutics reported a 26% increase in revenue and completed the sale of $150 million in priority review vouchers, significantly strengthening its balance sheet. The company is focusing on expanding market coverage and providing support for ongoing clinical trials.